MiNK Therapeutics, Inc. INKT
MiNK Therapeutics, Inc. (Nasdaq: INKT) is a respiratory drug developer. Its lead program, agenT-797, is in Phase 2 for severe pneumonia / moderate-to-severe hypoxemic acute respiratory failure (critical pulmonary immune failure). Its next catalyst on record is agenT-797: First patient dosing in investigator-sponsored GvHD prevention Phase 1 trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: agenT-797 — First patient dosing in investigator-sponsored GvHD prevention Phase 1 trial (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| agenT-797 (randomized adaptive Phase 2) | severe pneumonia and hypoxemic acute respiratory failure | cell therapy | Phase 2 |
| agenT-797 + botensilimab/balstilimab, ramucirumab, paclitaxel (investigator-sponsored Phase 2, MSK) | advanced esophageal, gastric, GEJ adenocarcinoma | cell therapy | Phase 2 |
| agenT-797 (Phase 1) | refractory solid tumors (34 patients enrolled) | cell therapy | Phase 1 |
| agenT-797 (investigator-sponsored Phase 1, Univ. of Wisconsin) | graft-versus-host disease prevention | cell therapy | Phase 1 |
| MiNK-215 (FAP-CAR-iNKT) | solid tumors (NSCLC, colorectal models) | cell therapy | Pre-clinical |
| MiNK-413 (BCMA-CAR-iNKT) | multiple myeloma / BCMA-expressing cancers | cell therapy | Pre-clinical |
Recent results and decisions
- Aug 13, 2026positive Initial treated patients in randomized Phase 2 were alive at Day 28 with improved oxygenation and ventilator/vasopressor liberation; no major SAEs attributed (small, preliminary, blinded).
The initial agenT-797–treated patients were alive and afebrile at Day 28, with improved oxygenation and liberation from ventilator and vasopressor support.
Filing - May 1, 2026started First patient dosed in randomized Phase 2 trial C-1300-02 in Lviv, Ukraine in May 2026.
MiNK began dosing at First Lviv Territorial Medical Union in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine, within days of receiving Ministry of Health authorization.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.